Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $41.20

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $41.20.

A number of equities analysts have weighed in on BCAX shares. HC Wainwright boosted their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th.

Bicara Therapeutics Price Performance

BCAX stock opened at $13.09 on Friday. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09. The business has a fifty day simple moving average of $14.83.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BCAX. Vestal Point Capital LP raised its position in Bicara Therapeutics by 67.1% in the fourth quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock worth $12,368,000 after acquiring an additional 285,000 shares during the period. Wexford Capital LP bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $348,000. Red Tree Management LLC purchased a new stake in shares of Bicara Therapeutics in the 4th quarter worth $55,230,000. Nuveen Asset Management LLC bought a new position in Bicara Therapeutics in the 4th quarter worth $436,000. Finally, Orbimed Advisors LLC lifted its position in Bicara Therapeutics by 9.7% during the fourth quarter. Orbimed Advisors LLC now owns 298,301 shares of the company’s stock valued at $5,196,000 after purchasing an additional 26,391 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.